Katherine Zhou
@katherinezhoumd.bsky.social
Duke Hematology-Oncology Fellow. Interested in RNA, GI oncology, and predictive biomarkers. Alum of Duke IM Residency, UChicago Pritzker School of Medicine, Yale College.
Reposted by Katherine Zhou
Really cool study, not limited by the hematologic toxicity we have seen with other CD47 agents
20/31 #TumorBoardTuesday
🏫Mini Tutorial 17🏫
5) Phase 1/2, PT886 (CD47 x CLDN18.2 bispecific) in adv gastric/GEJ or PC (TWINPEAK, NCT05482893)
Promotes ADCC by NK cells, phagocytosis by macrophages
Part C, cohort 2: 1L adv PDAC w/ CLDN18.2 ≥2+ ≥10%, PT886 + chemo
Results pending
🏫Mini Tutorial 17🏫
5) Phase 1/2, PT886 (CD47 x CLDN18.2 bispecific) in adv gastric/GEJ or PC (TWINPEAK, NCT05482893)
Promotes ADCC by NK cells, phagocytosis by macrophages
Part C, cohort 2: 1L adv PDAC w/ CLDN18.2 ≥2+ ≥10%, PT886 + chemo
Results pending
February 5, 2025 at 1:48 AM
Really cool study, not limited by the hematologic toxicity we have seen with other CD47 agents
Reposted by Katherine Zhou
This was not an easy study to execute, in patients who have few other (if any) treatment options.
Here we can appreciate the monotherapy activity with a BiTE over a mAb.
Here we can appreciate the monotherapy activity with a BiTE over a mAb.
18/31 #TumorBoardTuesday
🏫Mini Tutorial 15🏫
Efficacy for 600 µg/kg in CLDN18.2 IHC 2+/3+ ≥10%:
27 pts, 8 PRs, 11 SDs, ORR 39.6%, DCR 70.4%
DOR and PFS not reached
🏫Mini Tutorial 15🏫
Efficacy for 600 µg/kg in CLDN18.2 IHC 2+/3+ ≥10%:
27 pts, 8 PRs, 11 SDs, ORR 39.6%, DCR 70.4%
DOR and PFS not reached
February 5, 2025 at 1:43 AM
This was not an easy study to execute, in patients who have few other (if any) treatment options.
Here we can appreciate the monotherapy activity with a BiTE over a mAb.
Here we can appreciate the monotherapy activity with a BiTE over a mAb.
Reposted by Katherine Zhou
Bispecifics are so in right now.
Learn more about them in this recent review: www.nature.com/articles/s41...
But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity
Learn more about them in this recent review: www.nature.com/articles/s41...
But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity
February 5, 2025 at 1:39 AM
Bispecifics are so in right now.
Learn more about them in this recent review: www.nature.com/articles/s41...
But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity
Learn more about them in this recent review: www.nature.com/articles/s41...
But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity
Reposted by Katherine Zhou
#TumorBoardTuesday
🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓
📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer
RT and bring others into the discussion‼️
🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓
📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer
RT and bring others into the discussion‼️
February 3, 2025 at 8:28 PM
#TumorBoardTuesday
🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓
📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer
RT and bring others into the discussion‼️
🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓
📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer
RT and bring others into the discussion‼️